Lenvatinib (Lenvima)
New oral anticancer drug Lenvima (lenvatinib) has recently been approved by Japan for the treatment of unresectable thyroid cancer. This is another important market that the drug has captured since it was approved by the United States in February of this year. Previously, lenvatinib was granted orphan drug status and priority review qualifications in the United States, Japan, and the European Union. The drug, as an innovative drug with significant public health benefits, will help address the severe unmet medical needs in the field of pajzsmirigyrák.
Eisai said Lenvima will become the new standard for clinical treatment of unresectable thyroid cancer. The industry is very optimistic about Lenvima, and it is expected that the drug will become a new cash cow for Eisai, with annual sales peaking at more than $ 1 billion.
According to Eisai’s official information, in a large phase III SELECT study, lenvatinib significantly prolonged the progression-free survival of radioiodine-refractory differentiated thyroid cancer compared to placebo (PFS: 18.3 months vs 3.6 months At the same time, a significantly higher proportion of patients in the lenvatinib treatment group achieved tumor volume reduction (65% vs 2%). In addition, in another phase II study in Japan, lenvatinib also showed good efficacy and tolerance for medullary thyroid cancer and undifferentiated thyroid cancer.
Based on these results, Lenvima was approved by the Japanese regulatory agency to become the first molecular targeted therapy for unresectable thyroid cancer (including differentiated thyroid cancer, medullary thyroid cancer, and undifferentiated thyroid cancer).
Currently, although most types of thyroid cancer can be treated, there are few options for treatment once it gets worse. Differential thyroid cancer (DTC) is the most common malignant thyroid tumor, and its incidence has steadily increased in recent years.
Lenvatinib is an oral multi-receptor tyrosine kinase (RTK) inhibitor with a novel binding mode. In addition to inhibiting other RTKs involved in tumor proliferation and oncogenic signaling pathways, it can also selectively inhibit vascular endothelial growth factor (VEGF) receptor kinase activity.
